Advanced chondrosarcomas: Role of chemotherapy and survival Journal Article
| Authors: | Italiano, A.; Mir, O.; Cioffi, A.; Palmerini, E.; Piperno-Neumann, S.; Perrin, C.; Chaigneau, L.; Penel, N.; Duffaud, F.; Kurtz, J. E.; Collard, O.; Bertucci, F.; Bompas, E.; Le Cesne, A.; Maki, R. G.; Ray, I.; Blay, J. Y. |
| Article Title: | Advanced chondrosarcomas: Role of chemotherapy and survival |
| Abstract: | Background: There are limited data about the role of chemotherapy in patients with advanced chondrosarcomas. Methods: The medical charts of 180 patients with advanced chondrosarcomas having received chemotherapy in 15 participating institutions between 1988 and 2011 were reviewed. Results: Median age was 52 years. Sixty-three percent of patients had conventional chondrosarcoma and 88% had metastatic disease. Combination chemotherapy was delivered in 98 cases (54.5%). One hundred and thirty-one patients (73%) received an anthracycline-containing regimen. Using RECIST, the objective response rate was significantly different according to histological subtype, being 31% for mesenchymal chondrosarcoma, 20.5% for dedifferentiated chondrosarcoma, 11.5% for conventional chondrosarcoma and 0% for clear-cell chondrosarcoma (P = 0.04). Median progression-free survival (PFS) was 4.7 months [95% confidence interval (CI) 3-6.5]. Performance status (PS) ≥2, number of metastatic sites ≥1 and single-agent regimen were independently associated with poor PFS. Median overall survival (OS) was 18 months (95% CI 14.5-21.6). PS, number of metastatic sites and palliative surgery were independently associated with OS. Conclusions: Conventional chemotherapy have very limited efficacy in patients with advanced chondrosarcoma, the highest benefit being observed in mesenchymal and dedifferentiated chondrosarcoma. These data should be used as a reference for response and outcome in the assessment of investigational drugs in advanced chondrosarcoma. © The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology All rights reserved. |
| Keywords: | chemotherapy; treatment; chondrosarcoma |
| Journal Title: | Annals of Oncology |
| Volume: | 24 |
| Issue: | 11 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2013-11-01 |
| Start Page: | 2916 |
| End Page: | 2922 |
| Language: | English |
| DOI: | 10.1093/annonc/mdt374 |
| PROVIDER: | scopus |
| PMCID: | PMC3811906 |
| PUBMED: | 24099780 |
| DOI/URL: | |
| Notes: | --- - Cited By (since 1996):1 - "Export Date: 2 December 2013" - "Art. No.: mdt374" - "CODEN: ANONE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work